Inogen, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)

3 Months Ended

Mar. 31, 2017

The activity for stock options under the Company’s stock plans is as follows:

								Remaining
								weighted-
						Weighted-		average		Per share
						average		contractual		average
				Price per		exercise		terms		intrinsic
	Options			share		price		(in years)		value
Outstanding as of December 31, 2016		2,355,527		$0.60-$58.95		$	28.22		5.42	$	38.95
Granted		—			—		—
Exercised		(157,412	)	0.60-46.66			13.80
Forfeited		(53,465	)	38.54-58.95			45.63
Expired		(33	)		8.70		8.70
Outstanding as of March 31, 2017		2,144,617		0.60-58.95			28.85		5.26		48.71
Vested and exercisable as of March 31, 2017		987,534		0.60-46.66			18.30		4.93		59.26
Vested and expected to vest as of March 31, 2017		2,063,240		$0.60-$46.66		$	28.57		5.25	$	48.99

Summary of Restricted Stock Units Activity

RSU activity for the three months ended March 31, 2017, is summarized below:

			Weighted-
			average grant
			date fair value
	Units		per share
Unvested as of December 31, 2016		—	$	—
Granted		5,700		73.26
Vested		—		—
Forfeited/canceled		—		—
Unvested as of March 31, 2017		5,700	$	73.26

Summary of Stock-based Compensation Expense

Stock-based compensation

Stock-based compensation expense recognized for the three months ended March 31, 2017 and March 31, 2016 was as follows:

	Three months ended
	March 31,
	2017		2016
Stock-based compensation expense by type of award:
Stock option plan awards	$	1,744	$	1,204
Restricted stock units		24		—
Employee stock purchase plan		123		91
Total stock-based compensation expense	$	1,891	$	1,295

For the three months ended March 31, 2017 and March 31, 2016, stock-based compensation expense recognized under ASC 718, included in cost of revenues, sales and marketing expense, general and administrative expense, and research and development expense was as follows:

	Three months ended
	March 31,
	2017		2016
Cost of revenue	$	191	$	119
Research and development		223		131
Sales and marketing		315		227
General and administrative		1,162		818
Total stock-based compensation expense	$	1,891	$	1,295